Valuation Abbott Laboratories London S.E.
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Delayed
London S.E.
21:30:22 15/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 102.90 USD | -3.03% |
|
-2.75% | -18.21% |
| 09-15 | Abbott Announces First Canadian Use of Volt Pulsed Field Ablation System to Treat Atrial Fibrillation | CI |
| 09-15 | Abbott Laboratories to Pay $385 Million to Settle Infant Formula Allegations | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 177,122 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -18.7% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 201,061 | 198,079 | 194,389 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -9.54% | -1.48% | -1.86% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 29x | 22.5x | 20x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.7x | 3.54x | 3.36x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.67x | 0.8x | 1.6x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.53x | 3.25x | 3.04x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4x | 3.63x | 3.34x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.5x | 13.7x | 12.3x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.2x | 15.2x | 13.6x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.6x | 22.2x | 20.3x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.75% | 4.5% | 4.93% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.51% | 2.68% | 2.83% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.53 | 4.553 | 5.106 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 72.8% | 60.2% | 56.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,204 | 54,528 | 58,247 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,989 | 14,491 | 15,854 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,319 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,303 | 7,978 | 8,906 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 102.36 | 102.36 | 102.36 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 29x | 4x | 15.48x | 2.51% | 177B | |
| 19.59x | 3.57x | 12.77x | 3.04% | 118B | |
| 17.44x | 0.2x | 12.75x | 0.75% | 60.78B | |
| 35.04x | 3.4x | 11.62x | 2.16% | 49.53B | |
| 27.4x | 6.74x | 17.36x | 1.46% | 48.29B | |
| 35.01x | 6.16x | 19.33x | -.--% | 32.96B | |
| 42.59x | 1.25x | 11.58x | 0.22% | 28.94B | |
| 42.22x | 7.4x | 26.55x | 0.25% | 25.48B | |
| 49.45x | 6.68x | 21.46x | 0.43% | 21.77B | |
| Average | 33.08x | 4.38x | 16.54x | 1.2% | 62.59B | |
| Weighted average by Cap. | 28.61x | 3.93x | 15.19x | 1.86% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
